EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression

Juliana Mira Hernandez, Logan R J Bailey, Victoria R Salemme, Christopher Y Ko, Erin Y Shen, Megan Ngim, Duong T Hoang, Melissa Corea, Julie Bossuyt, Jennifer M Davis, Donald M Bers, Bence Hegyi

Basic Research in Cardiology · 21.05.2026 · 121 (4) · 669-688

DOI: 10.1007/s00395-026-01184-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Basic Research in Cardiology, online erschienen am 21.05.2026. Verfasst von Juliana Mira Hernandez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of California, Davis, 451 Health Sciences Drive, Davis, CA, 95616, USA. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Sodium-Glucose Transporter 2 Inhibitors, Heart Failure. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, Stanford Diabetes Research Center, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective treatments for heart failure with preserved ejection fraction (HFpEF) are limited. Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, provides cardiovascular benefits for patients with HFpEF. SGLT2 expression is virtually absent in cardiomyocytes, hence the exact protective mechanism of empagliflozin is unclear. We aimed to study the effect of in vivo empagliflozin treatment on excitation–contraction coupling (ECC), electrophysiology, and gene transcription in a translational two-hit HFpEF mouse model that combines the obese-diabetic leptin receptor-deficient db/db mice with chronic aldosterone infusion ( db/db + Aldo). We performed morphometry, echocardiography, cardiomyocyte electrophysiology, intracellular Ca 2+ imaging, and whole-heart RNA-sequencing in empagliflozin-treated db/db + Aldo and vehicle control mice. In db/db + Aldo mice, empagliflozin (in vivo, 4 weeks) reduced the elevated plasma blood glucose (13 ± 5 mmol/L versus 23 ± 8 mmol/L) and BNP levels, prevented pulmonary congestion, and ameliorated diastolic dysfunction. However, empagliflozin did not reduce cardiac hypertrophy and obesity. In healthy control mice, empagliflozin had no functional effect. Chronic in vivo empagliflozin treatment in db/db + Aldo also normalized the changes in cardiomyocyte electrophysiology and Ca 2+ handling properties measured in the absence of empagliflozin in the perfusion solution during cell experiments, indicating a true phenotypic rescue. Differentially expressed gene clusters were identified characteristic of the db/db genotype, aldosterone, and empagliflozin treatments. Interestingly, empagliflozin did not just reverse the HFpEF-altered gene expression but shifted it further away from control to a new expression profile. We conclude that chronic in vivo empagliflozin treatment restores cardiomyocyte electrophysiological and ECC properties, ameliorates diastolic function in cardiometabolic HFpEF, and induces complex gene expression changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 InhibitorsHeart FailureObesityMyocytes, CardiacStroke VolumeVentricular Function, LeftAnimalsDisease Models, AnimalMaleMice, Inbred C57BLExcitation Contraction CouplingMiceGene Expression Regulation

Stichwörter der Autor:innen

Excitation–contraction couplingGene transcriptionHFpEFIon channelsPreclinical animal modelSGLT2 inhibitor

Substanzen

empagliflozinBenzhydryl CompoundsGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacology, University of California, Davis, 451 Health Sciences Drive, Davis, CA, 95616, USA.
  • Research Group Biogenesis, Faculty of Agricultural Sciences, Veterinary Medicine, University of Antioquia, Medellin, Colombia.
  • Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, USA.
  • Department of Lab Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Department of Pharmacology, University of California, Davis, 451 Health Sciences Drive, Davis, CA, 95616, USA. dmbers@ucdavis.edu.
  • Department of Pharmacology, University of California, Davis, 451 Health Sciences Drive, Davis, CA, 95616, USA. bhegyi@ucdavis.edu.

Förderung

  • NHLBI NIH HHS
  • Stanford Diabetes Research Center
  • NIGMS NIH HHS
  • American Heart Association
  • NIDDK NIH HHS
  • Health Resources in Action
  • National Heart, Lung, and Blood Institute
  • Fulbright Colombia

Zitieren

APA

Mira Hernandez, J., Bailey, L. R. J., Salemme, V. R., Ko, C. Y., Shen, E. Y., Ngim, M., Hoang, D. T., Corea, M., Bossuyt, J., Davis, J. M., Bers, D. M., & Hegyi, B. (2026). Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression. Basic Research in Cardiology, 121(4), 669-688. https://doi.org/10.1007/s00395-026-01184-7

Vancouver

Mira Hernandez J, Bailey LRJ, Salemme VR, Ko CY, Shen EY, Ngim M, et al. Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression. Basic Research in Cardiology. 2026;121(4):669-688. doi:10.1007/s00395-026-01184-7

BibTeX
@article{MiraHernandez2026,
  author = {Mira Hernandez, Juliana and Bailey, Logan R J and Salemme, Victoria R and Ko, Christopher Y and Shen, Erin Y and Ngim, Megan and Hoang, Duong T and Corea, Melissa and Bossuyt, Julie and Davis, Jennifer M and Bers, Donald M and Hegyi, Bence},
  title = {Empagliflozin restores cardiac function in obese-diabetic HFpEF mice but further alters gene expression},
  journal = {Basic Research in Cardiology},
  year = {2026},
  volume = {121},
  number = {4},
  pages = {669--688},
  doi = {10.1007/s00395-026-01184-7}
}
Kostenlos starten →